| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Transgenomic, Inc. |
| 5600 South 42nd Street, Omaha, NE 68107 * (402) 738-5480 |
| Business Description | The company provides innovative research tools to the life sciences industry. |
| Offering Information Company has | |||
| Trading As | TBIO (NASNTL) | Industry | Manufacturing (SIC 3826) |
| Type of Stock Offered | Common Shares | Filing Date | 3/10/00 |
| Domestic Shares Offered | 4,000,000 | Offer Date | 7/17/00 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 4,000,000 | Offer Price | $15.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.050 |
| Gross Proceeds | $60,000,000 | Selling | $0.630 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 20,037,200 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Lead Manager | (415) 439-3626 |
| Bear, Stearns & Co. Inc. | Co-manager | (212) 272-4850 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 11.577 | 18.935 | 23.035 | - | - |
| Income from Oper. | - | - | -3.218 | -1.975 | -6.884 | - | - |
| Net Income | - | - | -2.410 | -1.576 | -9.827 | - | - |
| E.P.S | - | - | -0.220 | -0.130 | -0.760 | - | - |
| Revenue Growth (%) | - | - | 63.56 | 21.653 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -8.74 | - | - | ||||
| Cash Flow - Inv. | -3.46 | - | - | ||||
| Cash Flow - Fin. | 12.17 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 19.86 | Current Assets | 13.02 | Current Ratio | 1.37 |
| Total Liab. | 21.96 | Current Liab. | 9.53 | Debt Ratio | 110.57% |
| Total Equity | -2.10 | Working Cap. | 3.49 | Debt to Equity Ratio | - |
| Cash | 0.15 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for expansion of manufacturing capability, sales and marketing costs, research and development costs, debt reduction and general working capital. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Kutak & Rock |
| Bank's Law Firm | Milbank, Tweed, Hadley & McCloy |
| Registrar/Transfer Agent | Norwest Bank of Minnesota |
| Auditor | Deloitte & Touche |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Collin J. D'Silva | 33.50 | |
| Douglas T. Gjerde, Ph.D. | 16.90 | |
| INVESCO Private Capital, Inc. | 14.10 | |
| Note: represents ownership of 5% or more prior to the offering. | ||